elastography-USG scores were shown to be higher in patients with sialometry of $\pm 1.5$ ml ($n=7$) (28 vs. 17, $p=0.01$, $t=1.81$, $t=1.95$, $p=0.006$ and $t=1.41$, $p=0.028$) and anti-Ro positivity ($n=24$) (24 vs. 13, $t=3.83$, $t=2.42$, $p=0.001$ and $t=2.62$, $p=0.003$). The patients with severe parotid involvement (inhomogeneity/hypoechoogenic areas $\geq 2$) had more frequent anti-Ro and anti-La positivity (80 vs. 42%, $p=0.004$ and 48 vs. 17%, $p=0.011$).

Abstract THU0372 – Table 1. Demographics and Clinical Characteristics of SjS patients.

Abstract THU0372 – Table 2. Disease Activity Indexes and SG-USG Scores of SjS Patients.

Conclusions: Hocevar scoring system of major salivary glands was found to be related to patient reported activity in SjS. USG scores were associated with reduced saliva secretion and anti-Ro positivity. Severe parotid involvement was shown to be related to anti-Ro and La positivity. Evaluation of SG-USG including different scoring systems and elastography might reflect function of the salivary glands.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7099

THU0374 FACTORS ASSOCIATED WITH HIGH-DOSE CORTICOSTEROID USE IN SLE PATIENTS POST INITIATION OF SLE THERAPY

K. Schroeder, J. Paik, R. W. Hoffman, S. Gelwicks, E. Lilly and Company; Former Eli Lilly and Company Employee, Indianapolis, USA

Background: Systemic lupus erythematosus (SLE) therapies include non-steroi-dal anti-inflammatory drugs, antimarials, systemic immunosuppressants, and biologics with corticosteroids as necessary. The majority of these current therapies are only partially effective in disease control. Despite treatment, patients may experience flares of disease activity, which can lead to progressive end-organ damage. Severe flares may require intensive immunosuppression, including with high-dose corticosteroids, with risk including end-organ damage.

Objectives: To understand the unmet need in SLE by quantifying use of high-dose ($\geq 40$ mg/day) corticosteroids and determining factors associated with its use.

Methods: This study utilised the Truven MarketScan commercial claims database. Patients were indexed on first use of antimalarial, oral immunosuppressant or biologic during 2012–2013 (first use determined based on no claims for the 3 drug classes during the 1 year pre-index). Included patients had 2 recorded SLE diagnoses, were 18–50 years of age and had continuous medical and prescription enrollment from baseline through the 2 year follow-up. Patients with other pre-specified autoimmune disorders or cancers during the study period (baseline through follow-up) were excluded. During follow-up, fill of at least 1 high-dose corticosteroid prescription was assessed and associative logistic regression modeling performed.

Results: 1,401 patients (93% female; mean age 38.4 years) met the study criteria; 79% were indexed on an antimalarial, 15% on an oral immunosuppressant, 1% on a biologic and 5% on a combination of at least 2 of the aforementioned classes. 16% patients received a diagnosis code for nephritis or chronic kidney disease (CKD), 3% for myocarditis or pericarditis, and 13% for thrombocytopenia or leukopenia. During baseline, 56% of patients had at least 1 visit to a rheumatologist and 13% filled at least 1 high-dose corticosteroid prescription. During follow-up, 22% of patients had at least 1 high-dose corticosteroid prescription. Factors significantly associated (p<0.05) with high-dose corticosteroids during follow-up included: baseline rheumatologist visit (OR=0.62; 95% CI=0.47–0.82), number of SLE medication classes received during follow-up (OR=1.85; 95% CI=1.36–2.51), receipt of high dose corticosteroid during baseline (OR=5.21; 95% CI=3.60–7.53), nephritis or CKD (OR=1.85; 95% CI=1.29–2.64), myocarditis/pericarditis (OR=3.38; 95% CI=1.75–6.55), and thrombocytopenia/leukopenia (OR=1.70, 95% CI=1.17–2.48).

Conclusions: A number of baseline factors were associated with high-dose corticosteroid treatment during the follow-up period; one notable factor is the high percentage of patients using high-dose corticosteroids ($\geq 40$ mg/day). This indicates
THU0375 QUALITY OF LIFE IN INDIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN DURABLE REMISSION: PSYCHOSOCIAL AND DEMOGRAPHIC FACTORS

1Department of Rheumatology, IPGMER, Kolkata, India, Institute of Post Graduate Medical Education and Research; 2Department of Clinical Psychology, Institute of Psychiatry, Kolkata, India

Background: Remission in systemic lupus erythematosus (SLE) is uncommon. Detrimental effect of disease activity on quality of life (QoL) is reported but literature on QoL in lupus patients in durable remission is scant.

Objectives: To study QoL in Indian SLE patients in durable remission

Methods: We retrospectively included female SLE patients fulfilling ≥4 SLICC Classification Criteria, followed regularly at our clinic, who were in durable remission as determined by European consensus criteria (complete/clinical remission 3-months free of immunosuppressive drugs). QoL was assessed with Medical Outcome Study Short-Form-12 (SF-12). We also collected data on demographics (age, duration of disease, years of education), duration and quality (complete versus clinical) of remission and patient reported fatigue through fatigue severity scale (FSS). A structured interview with a clinical psychologist using ICD-10 Diagnostic Criteria for Research (DCR) was performed to diagnose depression. Age matched female control subjects were also included and underwent similar exercises. Association of physical and mental component summary scores (PCS and MCS) of SF-12 against depression, quality and duration of remission, duration of disease, years of education and FSS were tested with generalised linear models using Gamma regression with log-link function.

Results: We included 106 female SLE patients (age: 28.9±7.6 years; duration of disease: 45.1±34.8 months; years of education: 9.6±5.2; depression present in 95 (90.5%) and 98 female controls (age: 30.4±7 years; years of education: 10.8±6.2; depression present in 32 (32.7%)). At last visit, clinical remission was present in 68 (62.4%) and complete remission in 38 (35.2%). Duration of remission achieved were:<1 year in 17 (16%), 1–2 years in 40 (37.7%), 2–3 years in 18 (17%) and >3 years in 31 (29.2%). Steroid-free remission was present in 64 (60.3%) and the rest 42 (39.6%) were on ≤5 mg/d prednisolone. All were on hydroxychloroquine. A stable dose of 2nd immunosuppressive drug was present in 54 (50.9%) with 3 on stable dose of mycophenolate and 51 on azathioprine. SLE patients had comparable SF-12 PCS (48.4±8.1 vs 47.1±7, p=0.098) and MCS (57.7±3.4 vs 56.6±5.6, p=0.199) as compared to controls. Among lupus patients, both PCS (r=0.269, p=0.005) and MCS (r=0.298, p<0.001) were correlated with FSS and years of education (with PCS, r=0.215, p=0.027; with MCS, r=-0.269, p=0.005). Independent predictors of PCS were: clinical remission (Odd’s ratio (OR) 0.95, 95% confidence interval (CI) 0.92–0.99, p=0.033), FSS (OR 0.90, 95% CI 0.89–0.92, p=0.001) and disease duration <5 years (OR 0.92, 95% CI 0.86–0.97, p=0.006). Independent predictors of MCS were: FSS (OR 0.991, 95% CI 0.983–0.999, p=0.025), years of education (OR 0.998, 95% CI: 0.995–0.999, p=0.028) and disease duration <5 years (OR 1.053, 95% CI 1.018–1.089, p=0.003). Estimated marginal means of PCS and MCS against quality of remission and duration of disease are plotted in figure 1.

Conclusions: Indian lupus patients in durable remission had similar physical and mental QoL compared to healthy controls. Physical QoL was better in patients with complete remission, longer disease duration and low fatigue. Mental QoL was better in patients with low fatigue, less education and longer disease duration.

Disclosure of Interest: None declared


THU0376 CHARACTERISTICS OF PRIMARY SJÖGREN’S SYNDROME PATIENTS WITH MORPHOLOGICAL CHANGES OF THE PAROTID GLANDS IN MR IMAGING

1Department of Rheumatology and Immunology, 2Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

Background: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disease characterised by injury of exocrine glands, and a considerable proportion of pSS patients develop extraglandular involvement. The parotid glands are the most frequently involved glands in pSS. Conventional parotid examinations, such as X-Ray sialography and 99mTechnetium ([99mTc]) pertechnetate scintigraphy, played an important role in the diagnosis of pSS. However, X-Ray sialography only shows the abnormality of parotid ductal system and there is exposure to radionuclides with 99mTechnetium. Both examinations are invasive, while MR imaging is noninvasive, radiation-free, and sensitive to the morphological and signal changes of the parotid glands. MR sialography could be used to evaluate the parotid ductal system without the need for a contrast agent. But the clinical application value of parotid grand MR imaging in pSS patients has not been verified.

Objectives: The purpose of this study was to investigate the morphological changes of the parotid glands in MR imaging in patients with pSS and the correlations between morphological changes and the clinical manifestations.

Methods: Ninety-nine pSS patients who underwent parotid 3.0 Tesla MR imaging (T1, T2 and T2 STIR) were enrolled in this study. The morphological changes of the parotid glands (grades 0–3) and ducts (grades 0–4) were rated according to our previous studies. Patients were divided into normal parotid MR group (both glands grade 0 and ducts grade 0) and abnormal parotid MR group. The correlations between morphological changes of the parotid glands and clinical or serological characteristics were analysed by chi-square test.

Results: There were 93 females (93.9%) and 6 males (6.1%) in this study. The mean age and median disease duration were 47.4 years and 24 months. There were 50 (50.5%) pSS patients in parotid grand grade 0, 27 (27.3%) in grade 1, 15 (15.2%) in grade 2 and 6 (6.1%) in grade 3 (Fig 1A), and there were 53 (53.5%) pSS patients in parotid duct grade 0, 15 (15.2%) in grade 1, 17 (17.2%) in grade 2, 4 (4.0%) in grade 3, and 10 (10.1%) in grade 4 (Fig 1B). We found that patients in abnormal parotid MR group presented lower positive rates of myasthenia and higher positive rates of xerostomia, Schimer’s test, serum anti-SSA antibodies, anti-Ro-52 antibodies, antinuclear antibodies (ANA), rheumatoid factor (RF), plasma globulin, immunoglobulin G (IgG), and Hashimoto thyroiditis (p<0.05). But no significant difference was observed between two groups in the incidence of salivary gland enlargement, articular involvement, dermatological involvement, interstitial lung disease, tubulointerstitial nephritis and primary biliary cirrhosis.

Conclusions: The results indicated that parotid MR imaging is a noninvasive, radiation-free examination with a potential role in diagnosing pSS. pSS patients with morphological changes of the parotid glands in MR imaging were more likely to have xerostomia, hyperglobulinemia and thyroid involvement.

Disclosure of Interest: None declared